Patent or proprietary medicine classification turns on distinctive labeling and trade connection, with shorter limitation denied for lack of specific knowledge.

A medicinal product appearing in the Indian Pharmacopoeia may still fall within the patent or proprietary medicine tariff entry if its label or stylised marking indicates a trade connection with the manufacturer, even where the mark is unregistered. On that basis, Dextrose I.P. was treated as classifiable under Tariff Item 14E against the assessee. The plea for the shorter limitation period also failed because mere visits by excise officers did not establish specific departmental knowledge of the labels or manufacturing activity; the demand was therefore not confined on limitation grounds.

---

---

Issues: (i) whether Dextrose I.P., though appearing in the Indian Pharmacopoeia, was classifiable as patent or proprietary medicine under Tariff Item 14E because of the label and calligraphic letters used by the manufacturer, and (ii) whether the demand was barred in part by the shorter period of limitation instead of the longer period.

Issue (i): whether Dextrose I.P., though appearing in the Indian Pharmacopoeia, was classifiable as patent or proprietary medicine under Tariff Item 14E because of the label and calligraphic letters used by the manufacturer.

Analysis: The definition of patent or proprietary medicine under the tariff item covered a drug or medicinal preparation bearing, on itself or its container, a name not specified in a notified pharmacopoeia, or a brand name or other mark such as a symbol, monogram, label, signature, invented word, or writing used to indicate a connection in the course of trade between the medicine and some person having the right to use the mark. The medicine was in the pharmacopoeia, but the label carried two stylised letters and the manufacturer's name, which were treated as a distinctive mark indicating trade connection. The Tribunal preferred the view that such a mark was sufficient even though the trade mark was not registered.

Conclusion: Dextrose I.P. was held to fall within Tariff Item 14E as a patent or proprietary medicine, against the assessee.

Issue (ii): whether the demand was barred in part by the shorter period of limitation instead of the longer period.

Analysis: The assessee had not filed the declaration required to claim exemption from licensing control. Mere general visits by excise officers did not establish that the department had specific knowledge of the labels and the manufacturing activity so as to confine the demand to the shorter period. The record was insufficient to impute such knowledge to the department.

Conclusion: The claim for the shorter period of limitation was rejected, against the assessee.

Final Conclusion: The classification adopted by the department was upheld and the duty demand survived; the appeal was dismissed.

Ratio Decidendi: A stylised label or mark on a medicinal product can attract the patent or proprietary medicine tariff entry if it indicates a trade connection with the manufacturer, even where the product appears in a pharmacopoeia and the mark is unregistered; absence of specific departmental knowledge defeats a plea for the shorter limitation period.

---